Breaking News Instant updates and real-time market news.

GE

General Electric

$23.83

0.25 (1.06%)

, PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

16:31
10/20/17
10/20
16:31
10/20/17
16:31

On The Fly: Top stock stories for Friday

Stocks opened sharply higher and remained in positive territory for the entire session following the passage of a budget in the Senate, which was read as a sing of potential progress toward the Trump administration's long-awaited tax reform plan. The early strength came despite the poor earnings report from General Electric (GE), which missed Wall Street estimates and cut its outlook. As GE's share price recovered, the Dow and S&P stretched their gains with the Dow zooming past the 23,300 level. ECONOMIC EVENTS: In the U.S., existing home sales rose 0.7% to a 5.39M rate in September, which was better than forecast and breaks a string of three straight monthly declines. On the political front, the Senate passed a budget resolution Thursday night. Of note, the Senate resolution was apparently adjusted to accommodate demands from House Republicans, meaning the House is expected to pass the measure next week, taking another step toward a potential tax reform agreement. In energy news, Baker Hughes reported that the U.S. rig count is down 15 rigs from last week to 913. COMPANY NEWS: Shares of General Electric were in focus after the company reported quarterly profit that widely missed consensus estimates and cut its outlook for fiscal 2017 as new CEO John Flannery called the results "unacceptable." Flannery said the company is "focused on redefining our culture, running our businesses better, and reducing our complexity" and added that "there are no sacred cows" in the company's review... Shares of Procter & Gamble (PG), which recently declared a win in its proxy battle with activist Nelson Peltz, fell 3.65% after it reported first quarter sales and earnings that were roughly in line with expectations, adding that the start keeps the company on track to deliver on its fiscal year targets... Meanwhile, Celgene (CELG) shares fell 10.76% after a Data Monitoring Committee's recommended the discontinuation of a clinical study of GED-301 for Crohn's disease. The news prompted downgrades to Neutral at Citi and Baird, and price target cuts at a number of other firms... Additionally, Synchronoss (SNCR) shares were in focus after Reuters reported that Siris Capital has lined up $650M in loans to finance its roughly $1B buyout of Intralinks (IL) from Synchronoss. MAJOR MOVERS: Among notable companies up after earnings were Skechers (SKX), which jumped 41.45%, and Paypal (PYPL), which gained 5.5%. Some noteworthy losers after reporting earnings were NCR Corp (NCR), which slid 10.8%, and LaSalle Hotel (LHO), which fell 6.4%. INDEXES: The Dow rose 165.59, or 0.71%, to 23,328.63, the Nasdaq gained 23.99, or 0.36%, to 6,629.05, and the S&P 500 advanced 13.11, or 0.51%, to 2,575.21.

GE

General Electric

$23.83

0.25 (1.06%)

PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

CELG

Celgene

$121.33

-14.63 (-10.76%)

SNCR

Synchronoss

$11.39

-0.12 (-1.04%)

IL

Bought by SNCR

SKX

Skechers

$33.99

9.96 (41.45%)

PYPL

PayPal

$70.97

3.72 (5.53%)

NCR

NCR Corp.

$33.05

-4 (-10.80%)

LHO

LaSalle Hotel

$28.52

-1.94 (-6.37%)

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 29

    Nov

  • 30

    Nov

GE General Electric
$23.83

0.25 (1.06%)

10/20/17
JPMS
10/20/17
NO CHANGE
JPMS
GE management 'fighting to salvage value,' says JPMorgan
JPMorgan analyst C. Stephen Tusa says this morning's Q3 results from General Electric reinforce his view that while the "reset" of expectations is happening, a scenario of "lower for longer" looks increasingly more realistic. The analyst keeps an Underweight rating on the shares with a $20 price target. Management is "fighting to salvage value, not a simple restructuring," Tusa tells investors in a post-earnings research note. "The bottom line is that there are more questions than answers here," the analyst adds. He does not see how a "material dividend cut cannot be in the cards," with 65c in GAAP Industrial earnings and essentially no ongoing free cash flow at Industrial this year. General Electric shares in premarket trading are down 6% to $22.07.
10/20/17
SBSH
10/20/17
NO CHANGE
Target $31
SBSH
Buy
General Electric shares could be approaching a bottom, says Citi
Citi analyst Andrew Kaplowitz says this morning's earnings report indicates that the mounting challenges developing over time in General Electric's Power business now appear to be fully materializing. Investor expectations have been coming down and today's results can be viewed as a first step in a reset of expectations, Kaplowitz tells investors in a post-earnings research note. The analyst sees the stock coming under incremental near-term pressure, but thinks the shares "could potentially be approaching a bottom" as expectations begin to reset. Kaplowitz has a Buy rating on GE with a $31 price target. The stock in premarket trading is down 8% to $21.65.
10/20/17
DBAB
10/20/17
NO CHANGE
DBAB
Sell
Deutsche calls GE earnings miss 'shocking,' sees 'sizable' dividend cut
Deutsche Bank analyst John Inch calls General Electric's weaker than expected Q3 results this morning "shocking," noting earnings came in 20c below the 49c forecast while 2017 cash flow guidance was cut almost in half. The analyst points out the Industrial tax rate was a negative 4%. After subtracting up to $2B for required pension contribution and $3B-$4B in capital spending, GE "falls well short" of generating enough cash to pay its $8B common dividend from operations, which raises the prospects of a pending dividend cut and/or raising financial leverage to pay for the dividend, Inch tells investors in a research note. He believes the decline in earnings per share to just over $1.00 this year suggests that a "sizable dividend cut is pending." Inch believes the shares, at a 22 times price-to-earnings ratio, look "that much more expensive." He keeps a Sell rating on GE with a $21 price target. The shares in premarket trading are down 7% to $21.93.
10/18/17
JPMS
10/18/17
NO CHANGE
Target $20
JPMS
Underweight
JPMorgan lists dividend cut to 60c, exiting Baker Hughes as options for GE
JPMorgan analyst C. Stephen Tusa, while continuing to believe shares of General Electric (GE) should go lower, thinks a "myriad of potential moves" from the company are forthcoming. Visibility around potential actions will improve starting this Friday with the earnings report, Tusa tells investors in a research note. The analyst believes potential steps by management include raising $8B of debt for pension funding, undertaking a restructuring to save $2B-$3B, exiting Baker Hughes (BHGE) via a share exchange and selling the Transportation unit for a combined $30B-$35B, and/or cutting the dividend to 60c per share from the current 96c. The latter would free up $3B in additional available cash flow per year, Tusa points out. The analyst keeps an Underweight rating on GE shares with a $20 price target.
PG Procter & Gamble
$88.25

-3.34 (-3.65%)

10/18/17
JEFF
10/18/17
NO CHANGE
Target $104
JEFF
Buy
Jefferies likes setup for Procter & Gamble into Q1 results
Jefferies analyst Kevin Grundy says he likes the setup for Procter & Gamble into the company's Q1 earnings report on October 20. Expectations are low for the quarter, and the company has incentive to deliver strong results amid activist pressure from Trian, Grundy tells investors in a pre-earnings research note. He reiterates a Buy rating on Procter with a $104 price target.
10/10/17
JEFF
10/10/17
NO CHANGE
Target $104
JEFF
Buy
Peltz likely to 'stick around,' providing floor for P&G shares, says Jefferies
Jefferies analyst Kevin Grundy believes Trian's Nelson Peltz will remain invested in Procter & Gamble in the near-to-intermediate term after appearing to lose his proxy battle by a razor-thin margin. The activist's continued involvement should continue to raise the "execution bar" for P&G and provide a floor for the shares, said Grundy, who reiterates a Buy rating and $104 price target on the stock.
10/04/17
GSCO
10/04/17
DOWNGRADE
Target $87
GSCO
Neutral
Kraft Heinz downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Jason English downgraded Kraft Heinz (KHC) to Neutral and lowered his price target for the shares to $87 from $95. The analyst sees greater downside risk to estimates than upside with input cost pressure mounting. After updating his estimates across the Americas Consumer Staples group, English sees increasing risk to margin expectations as renewed input cost pressures challenge pricing power. He keeps Sell ratings on J.M. Smucker (SJM), General Mills (GIS), Church & Dwight (CHD) and Procter & Gamble (PG).
10/20/17
STFL
10/20/17
UPGRADE
Target $87
STFL
Buy
Procter & Gamble price target lowered to $87 from $90 at Stifel
Stifel analyst Mark Astrachan called Procter & Gamble's EPS beat "lower quality," noting that the company continues to grow sales below global category growth and that pre-tax income excluding corporate costs declined 3%. Following the report, he kept his FY18 and FY19 EPS estimates largely unchanged, but lowered his price target on P&G shares to $87 from $90 to reflect a lower multiple given the company's weakened fundamentals. Astrachan keeps a Hold rating on the stock.
CELG Celgene
$121.33

-14.63 (-10.76%)

10/20/17
FBCO
10/20/17
NO CHANGE
Target $145
FBCO
Outperform
Celgene setback with GED-301 manageable, says Credit Suisse
Credit Suisse analyst Alethia Young lowered her price target on Celgene to $145 from $156 after the company announced it has discontinued the GED-0301 Phase 3 program in Crohn's disease. It appears the trial was ended early due to efficacy, since there was no safety imbalance noted, Young said. GED-301 was the program where skepticism was the highest, Young tells investors, adding that she remains confident in ozanimod in ulcerative colitis and noting that ozanimod is also an option in Crohn's. She keeps an Outperform rating on Celgene, citing its "broad and diversified" pipeline, which she sees making this setback "manageable."
10/20/17
WELS
10/20/17
NO CHANGE
Target $163
WELS
Outperform
Celgene disappointment to be temporary, says Wells Fargo
Wells Fargo analyst Jim Birchenough views Celgene's discontinuation of development for GED-0301 for Crohn's Disease as a temporary disappointment. The analyst does not see any read-through to Celgene's anchor strategy in inflammatory bowel disease with Ozanimod, where he expects positive Crohn's disease data within weeks. He notes GED-0301 is not a contributor to his valuation or assumptions. Birchenough keeps an Outperform rating on Celgene with a $163 price target.
10/20/17
MSCO
10/20/17
NO CHANGE
Target $120
MSCO
Underweight
Morgan Stanley says Celgene may fall 5%-10% on 'major negative' of trial failure
Morgan Stanley analyst Matthew Harrison, who already had an Underweight rating on Celgene shares, called the company's halting of its Phase 3 GED-0301 program a "major negative" and predicted the stock will likely fall 5%-10% following the news. While it was known that GED-0301 was one of the more risky assets in Celgene's pipeline, Harrison also believes it was thought of as a significant potential driver of upside, which is now removed. He keeps a $120 price target on Celgene shares, which are down about 6% to $128.32 in pre-market trading.
10/20/17
10/20/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PulteGroup (PHM) downgraded to Sell from Neutral at Citi with analyst Will Randow saying the 49% year-to-date share rally has been exaggerated by the company's $1B share repurchase program that likely will sunset at year-end. 2. Celgene (CELG) was downgraded to Neutral from Buy at Citi and to Neutral from Outperform at Baird. 3. HP Enterprise (HPE) downgraded to Neutral from Buy at UBS with analyst Steven Milunovich saying the company's streamlining plans make sense but could prove disruptive and its pivot to higher margin revenue will take time. 4. Regeneron (REGN) downgraded to Underweight from Equal Weight at Barclays with analyst Geoff Meacham saying he believes expectations for Dupixent in atopic dermatitis and asthma are too high. 5. Bojangles (BOJA) downgraded to Market Perform from Outperform at Cowen with analyst Andrew Charles saying his survey data leaves him concerned whether the company can successfully implement value efforts to drive traffic amid intensified industry focus on value, which is likely to persist through 2018. Charles lowered his price target to $14 from $20 on Bojangles shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SNCR Synchronoss
$11.39

-0.12 (-1.04%)

09/20/17
DBAB
09/20/17
NO CHANGE
Target $10
DBAB
Hold
Synchronoss price target lowered to $10 from $18 at Deutsche Bank
Deutsche Bank analyst Nandan Amladi cut his price target for Synchronoss Technologies to $10 citing increased uncertainty after Siris Capital decided not to pursue an all-cash acquisition of the company. Yesterday's 40% selloff retraces the pre-offer levels in June, Amladi tells investors in a research note. He continues to believe an eventual transaction "provides a clean exit" for Synchronoss shareholders, given the "mounting complications" facing the company. The analyst keeps a Hold rating on the shares.
09/19/17
09/19/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) downgraded to Underperform from Market Perform at Wells Fargo with Wells Fargo with analyst Tom Nikic saying with consumers having filled their closets with athletic wear over the past seven years, the category "appears poised to take a breather for now." The analyst cut his price target for the shares to $13 from $17. 2. Kellogg (K) downgraded to Neutral from Overweight at Piper Jaffray with analyst Michael Lavery saying cereal could be at risk from shrinking center store space. 3. Nike (NKE) downgraded to Neutral from Positive at Susquehanna saying that his checks indicate that the North American and European businesses are decelerating as some key categories, especially basketball, have underperformed, resulting in excess inventory that will pressure sales and margins. 4. Synchronoss (SNCR) downgraded to Underperform from Outperform at Raymond James with analyst Tavis McCourt citing the news that Siris Capital is no longer interested in an all-cash transaction for all the outstanding shares of the company and has withdrawn its $18 per share bid from June 22. Further, the analyst believes it increasingly unlikely that the current strategic review will result in an acquisition at a premium and expects share to come under pressure and stay in the range prior to the Siris indication of interest. 5. Sony (SNE) downgraded to Neutral from Outperform at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/19/17
RAJA
09/19/17
DOWNGRADE
RAJA
Underperform
Synchronoss downgraded to Underperform from Outperform at Raymond James
Raymond James analyst Tavis McCourt downgraded Synchronoss (SNCR) two notches to Underperform from Outperform following news Siris Capital is no longer interested in an all-cash transaction for all the outstanding shares of the company and has withdrawn its $18 per share bid from June 22. Further, the analyst believes it increasingly unlikely that the current strategic review will result in an acquisition at a premium and expects share to come under pressure and stay in the range prior to the Siris indication of interest.
10/17/17
JPMS
10/17/17
NO CHANGE
JPMS
Neutral
JPMorgan views Synchronoss sale of Intralinks as positive
JPMorgan analyst Sterling Auty calls Synchronoss' sale of Intralinks to Siris Capital a positive transaction saying it gives the company adequate capital and the opportunity to "hit the reset button" focusing on Cloud, Messaging, and Digital Transformation. Auty keeps a Neutral rating on Synchronoss.
IL Bought by SNCR

12/07/16
WELS
12/07/16
NO CHANGE
WELS
Synchronoss deal has positive aspects, says Wells Fargo
After Synchronoss Technologies,(SNCR) agreed to buy secure content collaboration provider IntraLinks Holdings (IL), Wells Fargo says that the "transformative deal" will boost Synchronoss' revenue growth to the high teens level versus 12% now while reducing its high level of reliance on AT&T (T) for revenue. The firm thinks that the company's "growth and margin profile is more attractive after the deal than before it." It keeps an Outperform rating on the stock.
12/09/16
LTCO
12/09/16
DOWNGRADE
LTCO
Neutral
Intralinks downgraded to Neutral from Buy at Ladenburg
Ladenburg Thalmann analyst Glenn Mattson downgraded Intralinks (IL) to Neutral citing the proposed acquisition of Synchronoss (SNCR).
01/11/17
RILY
01/11/17
DOWNGRADE
Target $13
RILY
Neutral
Intralinks downgraded to Neutral from Buy at B. Riley
B. Riley analyst Sarkis Sherbetchyan downgraded Intralinks to Neutral citing less potential of a superior takeover offer. The analyst lowered his price target for the shares to $13 from $15.
12/07/16
CHLM
12/07/16
DOWNGRADE
CHLM
Hold
Intralinks downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum downgraded Intralinks (IL) to Hold as it is being acquired by Synchronoss (SNCR) for $13 per share.
SKX Skechers
$33.99

9.96 (41.45%)

10/20/17
WEDB
10/20/17
UPGRADE
WEDB
Outperform
Skechers upgraded to Outperform from Neutral at Wedbush
10/20/17
SUSQ
10/20/17
NO CHANGE
Target $38
SUSQ
Positive
Skechers price target raised to $38 from $34 at Susquehanna
Susquehanna analyst Sam Poser raised his price target on Skechers to $38 from $34 citing international growth and healthy domestic business. He said continued top-line strength, coupled with slowing investment growth, sets the company up for an earnings inflection in 2018. Poser reiterated his Positive rating on Skechers shares.
10/20/17
10/20/17
UPGRADE
Target $35

Outperform
Skechers upgraded on sooner than expected inflection at Wedbush
As previously reported, Wedbush analyst Christopher Svezia upgraded Skechers to Outperform from Neutral following the company's Q3 earnings report, stating that the company's key drivers, particularly its international growth and gross margin, have inflected sooner than he expected. These factors, along with moderately improving U.S. wholesale sales, can drive continued outperformance, Svezia tells investors. He raised his price target on Skechers to $35 from $25.
10/20/17
EVER
10/20/17
NO CHANGE
EVER
Outperform
Evercore ISI initiates a 6% Skechers Long Position in Model Portfolio
Evercore ISI analyst Omar Saad initiated a 6% long Skechers position in the Model Portfolio. Saad said Skechers increasingly consistent financial performance confirms the company has transformed itself into a unique platform that adeptly designs, sources, and distributes a complex range of high-quality sneakers from fashion to casual to technical at a great value to consumers all over the world.
PYPL PayPal
$70.97

3.72 (5.53%)

10/20/17
BARD
10/20/17
NO CHANGE
Target $80
BARD
Outperform
PayPal price target raised to $80 from $65 at Baird
Baird analyst Colin Sebastian raised his price target on PayPal to $80 citing strong Q3 results. He said it remains one of the best plays on e-commerce as the company continues to demonstrate accelerating growth across almost all key metrics including total payment volume, revenue, transaction growth, and net new customer additions. Sebastian reiterated his Outperform rating on PayPal shares.
10/20/17
RHCO
10/20/17
NO CHANGE
Target $75
RHCO
Hold
PayPal price target raised to $75 from $60 at SunTrust
SunTrust analyst Andrew Jeffrey raised his price target on PayPal to $75 following Q3 results, maintaining a Hold rating. Jeffrey says PayPal has a balanced risk-reward of at least a 15% P/E premium to the network and faces long-term competitive threats, taking a "guarded view toward sustainable Venmo monetization", though the company has done an impressive job to drive account growth and user engagement.
10/20/17
BMOC
10/20/17
NO CHANGE
Target $80
BMOC
Outperform
PayPal price target raised to $80 from $70 at BMO Capital
BMO Capital analyst Paulo Ribeiro raised his price target on Paypal to $80 following Q3 results and kept his Outperform rating. Ribeiro noted accelerating momentum in new accounts and increased engagement helping EPS growth, along with expansion in products and services. The analyst also says the company's initial FY18 outlook suggests strength in mobile total payment volume and an encouraging rollout of Venmo monetization.
10/20/17
RBCM
10/20/17
NO CHANGE
Target $83
RBCM
Outperform
PayPal price target raised to $83 from $65 at RBC Capital
RBC Capital analyst Daniel Perlin raised his price target on PayPal to $83 and maintained his Outperform rating following Q3 results. Perlin says the fundamentals on PayPal remain intact with total payment volume growth of 29%, account increase of 14%, and operating margin expansion of 150 basis points. Perlin says the valuation on PayPal should be modeled closer to tech and internet peers rather than payment networks with more mature business models.
NCR NCR Corp.
$33.05

-4 (-10.80%)

10/20/17
RBCM
10/20/17
NO CHANGE
Target $44
RBCM
Outperform
NCR Corp price target lowered to $44 from $47 at RBC Capital
RBC Capital analyst Daniel Perlin lowered hir price target on NCR Corp to $44 and maintained an Outperform rating after Q3 earnings. Perlin says the revenue miss and guidance cut were driven by weakness in ATMs, as large North American clients delayed orders while business in Asia/Middle East/Africa was soft. Lower license sales and continued investments in software also pressured margins, writes Perlin, bringing his valuation down toward the company's historical average.
10/20/17
JPMS
10/20/17
NO CHANGE
Target $45
JPMS
Overweight
NCR enters 'Hardware penalty-box again' after outlook, says JPMorgan
JPMorgan analyst Paul Coster says NCR Corp.'s "weak" outlook for Q4 will put the company in the "Hardware penalty-box again." The analyst cut his estimates and dropped his price target for the shares to $45 from $56 but keeps an Overweight rating on the name. The analyst cites valuation and easier year-over-year revenue and earnings comps in 2018 for his rating.
09/19/17
JPMS
09/19/17
NO CHANGE
JPMS
Overweight
JPMorgan proclaims cash is not dead, calls NCR and Diebold attractive
Cash is not dead and ATM shipments are growing, JPMorgan analyst Paul Coster tells investors in a research note. After declining year-to-date 15% and 10%, respectively, the analyst believes Diebold (DBD) and NCR Corp. (NCR) are attractively valued. He has an Overweight rating on NCR and Neutral rating on Diebold.
08/14/17
BNCH
08/14/17
NO CHANGE
Target $55
BNCH
NCR pullback an 'excellent' buying opportunity, says Benchmark
After hosting investor meetings with management, Benchmark analyst Daniel Kurnos says the recent pullback in shares of NCR Corp. provides an "excellent" buying opportunity. The analyst thinks NCR can get back to mid-single digit growth as early as 2018. He sees the company's broad scale platform unification and rationalization yielding "significant benefits" over the next five years. The analyst has a Buy rating on the shares with a $55 price target.
LHO LaSalle Hotel
$28.52

-1.94 (-6.37%)

08/24/17
08/24/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Teva (TEVA) downgraded to Underperform from Neutral at Credit Suisse by analyst Vamil Divan, saying that while Teva has dramatically reduced 2017 guidance, the core challenges they are facing should not fade anytime soon. The analyst pointed out that pricing pressure and increased competition in the U.S. generics business will remain, the appointment of a full-time CEO is still pending and the threat of generic competition to Copaxone 40mg still looms. 2. Lowe's (LOW) downgraded to Market Perform from Outperform at BMO Capital by analyst Wayne Hood based on the company's results and guidance which he said were "disappointing." The analyst expects the company's profitability to remain "challenged" going forward. 3. Dick's Sporting (DKS) downgraded to Market Perform from Outperform at Cowen, saying it had overestimated the company's ability to achieve its prior guidance and maintain its profitability. Cowen pointed to a number of headwinds for Dick's, including increasing digital competition and the negative side of industry cyclical trends. 4. J.M. Smucker (SJM) downgraded to Neutral from Overweight at JPMorgan. 5. LaSalle Hotel (LHO) downgraded to Neutral from Outperform at Boenning & Scattergood by analyst Floris van Dijkum citing recent share outperformance and potential declining comparable EBITDA that could pressure future NAV. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/24/17
BOSC
08/24/17
DOWNGRADE
BOSC
Neutral
LaSalle Hotel downgraded to Neutral from Outperform at Boenning & Scattergood
Boenning & Scattergood analyst Floris van Dijkum downgraded LaSalle Hotel to Neutral citing recent share outperformance and potential declining comparable EBITDA that could pressure future NAV.
04/12/17
BOSC
04/12/17
INITIATION
Target $35
BOSC
LaSalle Hotel initiated with an Outperform at Boenning & Scattergood
Boenning & Scattergood analyst Floris van Dijkum initiated LaSalle Hotel with an Outperform and a $35 price target saying its largest market exposure is in Washington DC, which should serve well in 2017 as it traditionally does well in political administration transition years.
08/02/17
GSCO
08/02/17
DOWNGRADE
Target $24
GSCO
Sell
LaSalle Hotel downgraded to Sell from Neutral at Goldman Sachs
Goldman analyst Stephen Grambling downgraded LaSalle Hotel to Sell with a $24 price target saying it has among the greatest fundamental risk from a continued slowdown in corporate spending due to exposure to urban markets and shares trade at a premium.

TODAY'S FREE FLY STORIES

HIFS

Hingham Institution

$201.40

3.33 (1.68%)

16:04
11/21/17
11/21
16:04
11/21/17
16:04
Hot Stocks
Hingham Institution declares special dividend of 34c per share »

Hingham Institution…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLPG

Galapagos NV

$92.98

-0.41 (-0.44%)

16:03
11/21/17
11/21
16:03
11/21/17
16:03
Hot Stocks
Galapagos NV initiates phase 1 CF study of GLPG3221 »

Galapagos NV announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,126.31

-3.57 (-0.32%)

15:57
11/21/17
11/21
15:57
11/21/17
15:57
Hot Stocks
Amazon cuts prices for AWS IoT customers by 20%-40% »

Amazon said this…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

T

AT&T

$34.42

-0.22 (-0.64%)

, TWX

Time Warner

$89.35

1.64 (1.87%)

15:43
11/21/17
11/21
15:43
11/21/17
15:43
Hot Stocks
Trump says AT&T, Time Warner deal not good for the country »

President Donald Trump,…

T

AT&T

$34.42

-0.22 (-0.64%)

TWX

Time Warner

$89.35

1.64 (1.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

GES

Guess

$18.11

0.33 (1.86%)

15:40
11/21/17
11/21
15:40
11/21/17
15:40
Options
Active trading in Guess ahead of earnings »

Active trading in Guess…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

BZUN

Baozun

$36.16

0.66 (1.86%)

15:34
11/21/17
11/21
15:34
11/21/17
15:34
Options
Baozun options imply 15.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

OSUR

OraSure

$13.96

0.22 (1.60%)

15:32
11/21/17
11/21
15:32
11/21/17
15:32
Hot Stocks
OraSure jumps after $143M Oragene Dx devices deal »

Shares of OraSure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$102.94

0.185 (0.18%)

15:30
11/21/17
11/21
15:30
11/21/17
15:30
Periodicals
John Lasseter taking leave of absence from Pixar, notes 'missteps,' THR reports »

Disney Animation head…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLTR

Dollar Tree

$97.11

2.5 (2.64%)

15:28
11/21/17
11/21
15:28
11/21/17
15:28
Recommendations
Dollar Tree analyst commentary  »

Dollar Tree price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

MPB

Mid Penn Bancorp

$30.37

-0.7242 (-2.33%)

15:25
11/21/17
11/21
15:25
11/21/17
15:25
Hot Stocks
Mid Penn Bancorp declares quarterly dividend of 15c per share »

Payable on January 12,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPB

Mid Penn Bancorp

$30.37

-0.7242 (-2.33%)

15:24
11/21/17
11/21
15:24
11/21/17
15:24
Hot Stocks
Mid Penn Bancorp declares special dividend of 10c per share »

Payable on January 5,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IZEA

Izea

$4.35

-0.17 (-3.76%)

15:20
11/21/17
11/21
15:20
11/21/17
15:20
Hot Stocks
Breaking Hot Stocks news story on Izea »

Izea halted after jumping…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$48.61

-0.41 (-0.84%)

15:20
11/21/17
11/21
15:20
11/21/17
15:20
Options
Bullish option play opened in Oracle »

Bullish option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IZEA

Izea

$4.35

-0.17 (-3.76%)

15:19
11/21/17
11/21
15:19
11/21/17
15:19
Hot Stocks
Izea announces signing of 'one of largest grocery chains in U.S' »

In a tweet on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$16.45

0.01 (0.06%)

15:19
11/21/17
11/21
15:19
11/21/17
15:19
Options
GameStop options imply 15.6% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

ACIU

AC Immune

$10.37

-0.24 (-2.26%)

15:17
11/21/17
11/21
15:17
11/21/17
15:17
Conference/Events
AC Immune to hold a KOL luncheon meeting »

Key Opinion Leader (KOL)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
11/21/17
11/21
15:17
11/21/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
11/21/17
11/21
15:16
11/21/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:15
11/21/17
11/21
15:15
11/21/17
15:15
General news
Treasury Option Action: big buyer of put protection in the belly »

Treasury Option Action:…

UA

Under Armour

$11.47

-0.6 (-4.97%)

, UAA

Under Armour

$12.92

-0.52 (-3.87%)

15:11
11/21/17
11/21
15:11
11/21/17
15:11
Technical Analysis
Technical View: Under Armour near lows of the day, levels to watch »

The shares were last down…

UA

Under Armour

$11.47

-0.6 (-4.97%)

UAA

Under Armour

$12.92

-0.52 (-3.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMPI

DelMar Pharmaceuticals

$0.85

-0.0134 (-1.55%)

15:09
11/21/17
11/21
15:09
11/21/17
15:09
Hot Stocks
DelMar presents 'positive' interim results from VAL-083 study »

DelMar Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRQR

ProQR Therapeutics

15:06
11/21/17
11/21
15:06
11/21/17
15:06
Hot Stocks
ProQR Therapeutics treatment of retinitis pigmentosa granted FDA orphan status »

The FDA granted ProQR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

15:05
11/21/17
11/21
15:05
11/21/17
15:05
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

HPE

HP Enterprise

$14.16

0.065 (0.46%)

15:04
11/21/17
11/21
15:04
11/21/17
15:04
Options
Hewlett Packard Enterprise options imply 6.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

  • 11

    Dec

UA

Under Armour

$11.40

-0.675 (-5.59%)

, UAA

Under Armour

$12.88

-0.565 (-4.20%)

15:03
11/21/17
11/21
15:03
11/21/17
15:03
Periodicals
Head of footwear business leaving Under Armour, WSJ says »

Peter Ruppe, the senior…

UA

Under Armour

$11.40

-0.675 (-5.59%)

UAA

Under Armour

$12.88

-0.565 (-4.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.